Sequenom, New England Biolabs Ink Deal for Epigenetics Technology | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – New England Biolabs and Sequenom said after the close of the market on Tuesday they have signed a licensing and co-marketing agreement for the commercialization of tools for epigenetics research.

They also announced the launch of the first product stemming from the research collaboration, which served as the basis for the agreement, the EpiMark Methylated DNA Enrichment Kit from NEB.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.